CADL Candel Therapeutics
Candel Therapeutics earnings company data as of 4:48 AM ET 10/23
- 0 of 1 EPS beats
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | -0.24 | -0.52 | Miss |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by CADL's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $3M bought by 1 insider
- None no sales outside a trading plan
- $3.6M sold by 3 insiders under 10b5-1 plans
-
Paul Peter Tak CEOPlanned sale$3.2M 280,245 shares at $11.28 71% of stakeTraded Sep 10–11 Filed Sep 11
-
Seshu Tyagarajan Chief Technology OfficerPlanned sale$84K 7,000 shares at $12.00 8.3% of stakeTraded Aug 17 Filed Aug 19
-
Seshu Tyagarajan Chief Technology OfficerPlanned sale$70K 7,000 shares at $10.02 7.7% of stakeTraded Jun 29 Filed Jul 1
-
Francesca Barone Chief Scientific OfficerPlanned sale$236K 23,447 shares at $10.06 23% of stakeTraded Jun 29 Filed Jul 1
-
Paul B Manning DirectorBuy$3M 550,458 shares at $5.45 +25% to stakeTraded Feb 23 Filed Feb 26
Also filed in the last 12 months, not counted as buying or selling: 1 option exercise.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 5.07 | Filing Doc | |
| 8-K | 5.02,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 7.01,9.01 | Filing Doc | |
| 8-K | 2.02,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| DEF 14A | Filing Doc | ||
| DEFA14A | Filing Doc | ||
| SCHEDULE 13G/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 10-K | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.